StocksFundsScreenerSectorsWatchlists
CTLT

CTLT - Catalent Inc Stock Price, Fair Value and News

55.99USD+0.21 (+0.38%)Market Closed

Market Summary

CTLT
USD55.99+0.21
Market Closed
0.38%

CTLT Alerts

  • Big jump in Earnings (Y/Y)

CTLT Stock Price

View Fullscreen

CTLT RSI Chart

CTLT Valuation

Market Cap

10.1B

Price/Earnings (Trailing)

-9.41

Price/Sales (Trailing)

2.47

EV/EBITDA

-12.21

Price/Free Cashflow

-32.64

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

-35.09%

Return on Equity

-29.16%

Return on Assets

-10.76%

Free Cashflow Yield

-3.06%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

-10.88%

Rev. Growth (Qtr)

4.28%

CTLT Earnings

Earnings (TTM)

-1.1B

Earnings Growth (Yr)

100%

Earnings Growth (Qtr)

100%

Breaking Down CTLT Revenue

Last 7 days

-1.8%

Last 30 days

0.1%

Last 90 days

14.9%

Trailing 12 Months

33.1%

How does CTLT drawdown profile look like?

CTLT Financial Health

Current Ratio

2.48

Debt/Equity

1.34

Debt/Cashflow

0.04

CTLT Investor Care

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

-7.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.5B4.3B4.2B4.1B
20224.7B4.8B4.8B4.7B
20215.9B4.0B4.2B4.5B
20202.9B5.2B5.4B5.6B
20192.5B2.5B2.6B2.7B
20182.4B2.5B2.5B2.5B
20172.0B2.1B2.2B2.3B
20161.8B1.8B1.9B1.9B
20151.8B1.8B1.8B1.8B
20141.8B1.8B1.8B1.8B
20131.8B1.8B1.8B1.8B
201201.7B1.7B1.7B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Catalent Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
gunther scott
sold
-21,749
56.2
-387
svp, quality & reg. affairs
Jan 25, 2024
kreuzburg christa
sold (taxes)
-26,364
50.41
-523
-
Jan 16, 2024
hatzfeld michael
acquired
-
-
7,908
chief accounting officer
Dec 08, 2023
hopson ricky
sold (taxes)
-9,518
37.18
-256
pres. clinical dev supply div
Dec 08, 2023
maselli alessandro
acquired
-
-
3,761
president & ceo
Dec 08, 2023
gennadios aristippos
acquired
-
-
1,505
group pres. pharma & consumer
Dec 08, 2023
hopson ricky
acquired
-
-
747
pres. clinical dev supply div
Dec 08, 2023
gunther scott
acquired
-
-
1,023
svp, quality & reg. affairs
Dec 08, 2023
gennadios aristippos
sold (taxes)
-13,645
37.18
-367
group pres. pharma & consumer
Dec 08, 2023
maselli alessandro
sold (taxes)
-71,534
37.18
-1,924
president & ceo

1–10 of 50

Which funds bought or sold CTLT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 16, 2024
Pinnacle Bancorp, Inc.
unchanged
-
2,431
11,911
-%
Apr 16, 2024
MCF Advisors LLC
added
23.53
422
1,186
-%
Apr 16, 2024
Register Financial Advisors LLC
new
-
11,290
11,290
0.01%
Apr 16, 2024
NORRIS PERNE & FRENCH LLP/MI
added
-
3,502,760
17,161,000
1.23%
Apr 15, 2024
Sound Income Strategies, LLC
added
4,466
75,989
77,337
0.01%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
reduced
-27.17
-97,135
1,046,020
0.03%
Apr 15, 2024
FIRST CITIZENS BANK & TRUST CO
sold off
-100
-2,169,310
-
-%
Apr 15, 2024
Sunbelt Securities, Inc.
unchanged
-
1,059
5,193
-%
Apr 12, 2024
FIRST FINANCIAL CORP /IN/
new
-
6,265
6,265
-%
Apr 12, 2024
DNB Asset Management AS
reduced
-8.27
206,951
1,564,290
0.01%

1–10 of 50

Are Funds Buying or Selling CTLT?

Are funds buying CTLT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CTLT
No. of Funds

Unveiling Catalent Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
6.2%
11,209,374
SC 13G/A
Feb 14, 2024
nomura holdings inc
6.4%
11,487,158
SC 13G
Feb 13, 2024
janus henderson group plc
7.3%
13,249,339
SC 13G/A
Feb 13, 2024
vanguard group inc
11.17%
20,186,499
SC 13G/A
Feb 12, 2024
veritas asset management llp
3.58%
6,467,989
SC 13G/A
Feb 09, 2024
capital world investors
10.6%
19,113,006
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
16,175,385
SC 13G/A
Oct 10, 2023
capital world investors
10.0%
18,029,128
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
9.2%
16,578,946
SC 13G/A
Feb 13, 2023
capital world investors
7.7%
13,914,820
SC 13G/A

Recent SEC filings of Catalent Inc

View All Filings
Date Filed Form Type Document
Apr 15, 2024
DEFM14A
DEFM14A
Apr 09, 2024
S-8
Employee Benefits Plan
Apr 03, 2024
PREM14A
PREM14A
Mar 19, 2024
4
Insider Trading
Mar 15, 2024
144
Notice of Insider Sale Intent
Mar 12, 2024
144
Notice of Insider Sale Intent
Mar 01, 2024
8-K
Current Report
Feb 14, 2024
10-Q
Quarterly Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Catalent Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
348.8B
85.2B
-7.62% -10.06%
9.92
4.1
6.46% 95.94%
317.6B
60.1B
3.25% 9.20%
870.05
5.28
1.40% -97.49%
143.5B
46.5B
-8.33% -37.34%
-103.34
3.08
42.59% -114.62%
141.5B
28.2B
-2.53% 7.29%
21.07
5.02
7.09% 2.52%
83.4B
27.1B
-8.60% -20.08%
14.73
3.08
-0.60% 23.36%
14.8B
15.8B
-0.90% 54.57%
-25.67
0.93
6.17% 76.47%
MID-CAP
4.1B
4.7B
0.13% -17.24%
-320.65
0.87
4.58% 90.97%
4.0B
1.7B
-12.75% -17.88%
11.28
2.41
49.61% 324.78%
3.2B
8.8B
-7.68% 16.09%
-5.35
0.36
7.79% -163.11%
1.9B
644.4M
-6.53% -6.23%
14
2.99
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-10.42% -30.36%
-3.78
1.79
24.65% 80.36%
21.8M
1.3M
-17.83% -48.08%
-2.12
16.74
-98.14% -109.18%
17.1M
-
-12.17% 23.93%
-0.93
0.22
2882.68% -138.52%
2.5M
19.6M
-33.93% -94.71%
-0.18
0.13
80.00% 43.08%
472.0K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Catalent Inc News

Latest updates
Business Wire7 hours ago

Catalent Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.3%1,0249821,0551,0371,1491,0221,2871,2731,2171,0251,1881,0539118463,094761721665726618623
Gross Profit1.2%171169215180387258462423405324439366298249335239232178257199201
  S&GA Expenses22.0%250205217190226196226207228183184173165165157136141143143130123
EBITDA Margin-36.4%-0.30*-0.22*-0.02*0.06*0.16*0.16*0.17*0.18*0.22*0.23*0.22*----------
Interest Expenses-13.8%-66.00-58.00-56.00-51.00-47.00-32.00-32.00-33.00-32.00-26.00-31.50-27.00-26.00-26.00-20.40-34.40-34.90-36.30-31.00-26.40-25.50
Income Taxes163.2%24.00-38.00-67.00-55.0033.003.0017.0035.0018.0010.0039.0085.0021.00-15.0024.009.0013.00-6.909.0011.002.00
Earnings Before Taxes77.2%-182-797-177-2821143.0018517611510322231710967.0017930.0059.00-6.8080.0043.0051.00
EBT Margin-29.8%-0.35*-0.27*-0.08*0.00*0.10*0.10*0.12*0.13*0.17*0.18*0.18*----------
Net Income72.9%-206-759-110-22781.00-16814197.0093.0018323288.0082.0015421.0046.000.0071.0032.0049.00
Net Income Margin-32.2%-0.32*-0.24*-0.06*0.00*0.08*0.08*0.10*0.11*0.13*0.14*0.15*----------
Free Cashflow111.7%18.00-15458.00-20246.00-241-166-10.00-54.009.00-55.00----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q22023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets5.2%10,5089,98810,02310,77710,83011,14810,20610,50810,32210,20310,1839,1128,7698,1987,9847,7777,0806,1956,1206,1844,493
  Current Assets13.5%2,9172,5702,6142,6922,7382,9192,6992,9173,0252,9743,9312,9182,7752,5192,3562,2931,7461,3011,2671,3961,144
    Cash Equivalents-100.0%-2292092802524422814497868491,9698969888331,007953608189243345228
  Inventory-100.0%-775796777744818732702676688622563528461384324297250251257247
  Net PPE-100.0%-3,7773,7233,6823,6713,5793,1673,1272,8202,7272,5812,5242,3592,1302,0361,9011,7701,6181,5611,5371,302
  Goodwill-100.0%-2,3512,3163,0393,0233,2152,9293,0063,0123,0262,5312,5192,5152,4622,4902,4712,4492,2082,1962,2211,409
Liabilities-9.0%5,7336,3016,1826,1666,1276,2565,5265,7335,6905,7225,8034,8384,6974,3844,3064,2714,2853,8733,8643,8963,783
  Current Liabilities6.0%1,0981,0361,5341,5301,4871,5529691,0981,0461,0451,0961,1961,1391,024920893917658616671525
  Long Term Debt-100.0%-4,9594,3224,3134,2614,2214,0984,1714,1574,1914,2253,1663,1502,9842,9852,9452,9272,8252,8592,8832,116
Shareholder's Equity29.5%4,7753,6873,8414,6114,8924,9124,7004,7754,6324,4814,0213,9153,7133,4563,0722,8992,1881,7161,6491,6821,621
  Retained Earnings173.7%518-703-49726237261951851835020911425.00-150-377-460-535-681-694-731-723-790
  Additional Paid-In Capital-100.0%-4,7424,7244,7014,6974,6864,6744,6494,6304,6154,2344,2054,1864,1613,9013,8183,2612,7592,7552,7572,739
Accumulated Depreciation-100.0%-1,7561,6471,5961,5401,4651,3581,3471,3081,2151,2151,179---------
Shares Outstanding-100.0%-180180179180180180179179171171171170--------
Float----------7,900---17,710---8,200---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations260.0%112,000-70,000196,000-64,000214,000-92,00069,000138,00069,000163,000134,00075,00074,000150,000172,400121,700120,70025,20088,20075,30043,300
  Share Based Compensation-15.8%16,00019,000-6,00010,00019,00012,00010,00011,00021,00013,000----------
Cashflow From Investing-13.1%-95,000-84,000-121,000-110,000-608,000-116,000-394,000-191,000-1,132,000-167,000-213,000-82,000-203,000-151,000-162,200-465,600-114,300-84,900-1,252,300-48,900-43,000
Cashflow From Financing-114.3%-14,00098,000-51,000-25,000523,00074,0001,000-3,000-49,0001,082,000-17,000166,000-57,00050,000331,300772,500-66,000-35,8001,283,500-8,700-55,000
  Buy Backs--------------1,80083,600-494,200----200-

CTLT Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net revenue$ 1,024.0$ 1,149.0$ 2,006.0$ 2,171.0
Cost of sales853.0762.01,666.01,526.0
Gross margin171.0387.0340.0645.0
Selling, general, and administrative expenses250.0226.0455.0422.0
Goodwill, Impairment Loss(2.0)0.0(687.0)0.0
Other Cost and Expense, Operating35.023.036.025.0
Operating earnings(112.0)138.0(838.0)198.0
Interest expense, net66.047.0124.079.0
Other (income)/expense, net[1]4.0(23.0)17.02.0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total(182.0)114.0(979.0)117.0
Income tax expense24.033.0(14.0)36.0
Net earnings/(loss)$ (206.0)$ 81.0$ (965.0)$ 81.0
Earnings Per Share, Basic$ (1.13)$ 0.45$ (5.31)$ 0.45
Earnings Per Share, Diluted$ (1.13)$ 0.44$ (5.31)$ 0.45
[1]Other expense, net during the three months ended December 31, 2023 and 2022 primarily includes foreign currency remeasurement losses/gains.

CTLT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 229.0$ 280.0
Trade receivables, net843.01,002.0
Inventories775.0777.0
Prepaid expenses and other723.0633.0
Total current assets2,570.02,692.0
Property, plant, and equipment, net3,777.03,682.0
Other assets:  
Goodwill2,351.03,039.0
Other intangibles, net911.0980.0
Deferred Income Tax Assets, Net55.055.0
Other Assets, Noncurrent324.0329.0
Total assets9,988.010,777.0
Current Liabilities:  
Debt, Current46.0536.0
Accounts payable407.0424.0
Other accrued liabilities583.0570.0
Total current liabilities1,036.01,530.0
Long-term obligations, less current portion4,959.04,313.0
Pension liability101.0100.0
Deferred Income Taxes50.076.0
Other liabilities155.0147.0
Total liabilities$ 6,301.0$ 6,166.0
Common Stock, Par or Stated Value Per Share$ 0.01$ 0.01
Common Stock, Shares Authorized1,000,000,0001,000,000,000
Common Stock, Value, Outstanding$ 2.0$ 2.0
Preferred Stock, Value, Outstanding0.00.0
Additional paid in capital4,742.04,701.0
Accumulated deficit(703.0)262.0
Accumulated other comprehensive income/(loss)(354.0)(354.0)
Total shareholders' equity3,687.04,611.0
Total liabilities, redeemable preferred stock, and shareholders’ equity$ 9,988.0$ 10,777.0
Common stock, shares issued (shares)181,000,000180,000,000
CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
 CEO
 WEBSITEcatalent.com
 INDUSTRYPharmaceuticals
 EMPLOYEES17800

Catalent Inc Frequently Asked Questions


What is the ticker symbol for Catalent Inc? What does CTLT stand for in stocks?

CTLT is the stock ticker symbol of Catalent Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalent Inc (CTLT)?

As of Wed Apr 17 2024, market cap of Catalent Inc is 10.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTLT stock?

You can check CTLT's fair value in chart for subscribers.

What is the fair value of CTLT stock?

You can check CTLT's fair value in chart for subscribers. The fair value of Catalent Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalent Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTLT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalent Inc a good stock to buy?

The fair value guage provides a quick view whether CTLT is over valued or under valued. Whether Catalent Inc is cheap or expensive depends on the assumptions which impact Catalent Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTLT.

What is Catalent Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, CTLT's PE ratio (Price to Earnings) is -9.41 and Price to Sales (PS) ratio is 2.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTLT PE ratio will change depending on the future growth rate expectations of investors.